TNFα抑制剂治疗强直性脊柱炎研究进展

Advances of TNFα inhibitors in the treatment of ankylosing spondylitis

生物制剂如肿瘤坏死因子α(TNFα)抑制剂已在国内外用于强直性脊柱炎(AS)的临床研究,并取得明显疗效,对疾病活动性、患者的功能和生活质量改善明显。因有少量证据提示,TNFα抑制剂具有减慢AS患者放射学进展的作用,有学者建议应尽早使用,但目前关于该类药物的用药指征、疗效与不良反应等还存在一些争论,现对2种TNFα抑制剂英利昔单抗和依那西普治疗AS的临床研究进展及不良反应等进行综述。

The use of biological agents such as TNFot inhibitors has been implicated in the treatment of ankylosing spondylitis （AS）. Dramatic clinical benefits, including significant decrease in disease symptoms and improvements in function and quality of life, were reported. Recent evidences showed that TNFot inhibitors may retard the progression of radiological changes in AS patients. Some researchers even suggested that TNFot inhibitors should be used early in the disease process to achieve best clinical outcomes. This article reviews the use of infliximab and etanercept in AS patients together with discussions on their clinical indications, efficacy and side effects.